SCHEMBL473225

SCHEMBL473225

CC(C)(C)OC(=O)CCCO

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.47
CAMK2A Q9UQM7 1/20 0.40
EPHX2 P34913 1/20 0.40
TSHR P16473 2/20 0.39
VCAM1 P19320 2/20 0.36
HDAC1 Q13547 2/20 0.36
HDAC2 Q92769 2/20 0.36
HDAC6 Q9UBN7 2/20 0.36
HDAC8 Q9BY41 2/20 0.36
HDAC3 O15379 1/20 0.36
CYP4F2 P78329 2/20 0.34
CYP4A11 Q02928 2/20 0.34
STING1 Q86WV6 1/20 0.34
DGAT1 O75907 1/20 0.33
CYP2D6 P10635 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
CA7 P43166 1/20 0.33
MEN1 O00255 1/20 0.32
GAA P10253 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL28201423 0.98 TDP1 (0.46) TDP1CAMK2AEPHX2TSHRVCAM1
SCHEMBL934152 0.93 TDP1 (0.50) TDP1EPHX2TSHRVCAM1HDAC1
SCHEMBL16323750 0.91 TDP1 (0.53) TDP1EPHX2TSHRVCAM1HDAC1
SCHEMBL17296020 0.91 TDP1 (0.53) TDP1EPHX2TSHRVCAM1HDAC1
SCHEMBL3988979 0.91 TDP1 (0.53) TDP1EPHX2TSHRVCAM1HDAC1
SCHEMBL25168218 0.91 TDP1 (0.53) TDP1EPHX2TSHRVCAM1HDAC1
SCHEMBL8507410 0.91 TDP1 (0.53) TDP1EPHX2TSHRVCAM1HDAC1
SCHEMBL8033386 0.91 TDP1 (0.53) TDP1EPHX2TSHRVCAM1HDAC1
SCHEMBL22029385 0.91 TDP1 (0.53) TDP1EPHX2TSHRVCAM1HDAC1
SCHEMBL31240235 0.91 TDP1 (0.53) TDP1EPHX2TSHRVCAM1HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 477 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119930678-A Methoxyphos hapten, complete antigen, antibody and preparation method and application thereof 深圳市计量质量检测研究院 2025-05-06 CN claimed
CN-106478591-B A kind of method for splitting of Atorvastatin condensation product intermediate 北京嘉林药业股份有限公司 2018-11-13 CN claimed
US-9957214-B2 Multifunctional radical quenchers ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2018-05-01 US claimed
US-20150274628-A1 MULTIFUNCTIONAL RADICAL QUENCHERS ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2015-10-01 US claimed
EP-2906207-A1 MULTIFUNCTIONAL RADICAL QUENCHERS Arizona Board of Regents on behalf of Arizona State University (US) 2015-08-19 EP claimed
WO-2014059158-A1 MULTIFUNCTIONAL RADICAL QUENCHERS ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA, ACTING FOR AN ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2014-04-17 WO claimed
CN-101248054-B Thiazole derivatives and use thereof MERCK SERONO SA 2012-05-09 CN claimed
CN-101248054-A Thiazole derivatives and use thereof SERONO LAB (CH) 2008-08-20 CN claimed
EP-0454501-B1 Benzylidenethiazolidine derivatives, their preparation and their use for the inhibition of lipid peroxides SANKYO CO (JP) 2001-09-05 EP claimed
EP-0839812-A1 Preparation of benzylthiazolidine derivatives Sankyo Company Limited (JP) 1998-05-06 EP claimed
EP-0454501-A2 Benzylidenethiazolidine derivatives, their preparation and their use for the inhibition of lipid peroxides Sankyo Company Limited (JP) 1991-10-30 EP claimed
JP-10045672-A None JP disclosed
EP-4003988-B1 3,6-DIAMINO-PYRIDAZIN-3-YL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS PRO-APOPTOTIC AGENTS SERVIER LAB (FR) 2026-05-20 EP disclosed
EP-4727537-A2 SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF Adaxion Therapeutics, Inc. (US) 2026-04-22 EP disclosed
EP-4719486-A1 CONJUGATES AND USES THEREOF Full-Life Technologies UK Limited (GB) 2026-04-08 EP disclosed
EP-0620003-A1 VASOPRESSIN ANTAGONIST AND OXYTOCIN ANTAGONIST OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1994-10-19 EP disclosed
CN-1090278-A Blood vessel tension peptide protoenzyme inhibitor-N-(2-amino-2-oxygen ethyl) succinic diamide derivative BIO MEGA BOEHRINGER INGELHEIM (CA) 1994-08-03 CN disclosed
WO-1994005627-A1 HYDROXAMIC ACID-BASED BIFUNCTIONAL CHELATING COMPOUNDS UAB RESEARCH FOUNDATION (US) 1994-03-17 WO disclosed
WO-1994000119-A1 AMINOBUTANOIC ACID COMPOUNDS HAVING METALLOPROTEASE INHIBITING PROPERTIES GLAXO INC. (US) 1994-01-06 WO disclosed
EP-0454501-A2 Benzylidenethiazolidine derivatives, their preparation and their use for the inhibition of lipid peroxides Sankyo Company Limited (JP) 1991-10-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150274628-A1 MULTIFUNCTIONAL RADICAL QUENCHERS SQOR, UQCRC1, PRDX5 TDP1 392/4885CAMK2A 4120/4885EPHX2 2040/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.